WESTBROOK, Maine, Jan. 21, 2019 /PRNewswire/ -- IDEXX Laboratories,
Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics and
software, today announced that it is introducing a new canine
progesterone test for Catalyst Dx® and Catalyst
One® chemistry analyzers. This much-anticipated in-house
diagnostic will help veterinarians determine when a dog is ready to
breed by providing a reliable, quantitative, point-of-care measure
of progesterone levels to ascertain ovulation status. IDEXX will
begin shipping the new test by the end of March, with initial
availability in the United States,
Canada, the United Kingdom, France, Germany, and Austria, and will continue shipping to other
countries over the course of 2019.
![(PRNewsfoto/IDEXX Laboratories, Inc.) (PRNewsfoto/IDEXX Laboratories, Inc.)](https://mma.prnewswire.com/media/810459/IDEXX_Laboratories_Logo.jpg)
IDEXX estimates that about a quarter of veterinary clinics in
the United States provide
reproductive management services.1 Canine ovulation
occurs only once or twice a year, so a missed breeding opportunity
can be costly for clients. As the human-pet bond continues to
strengthen, puppies from qualified, responsible breeders are often
in high demand. With quantitative benchtop results in 12 minutes,
the Catalyst® Progesterone Test provides a powerful tool
for enabling veterinarians to pinpoint the optimal breeding window
to better ensure successful breeding events.
"IDEXX's new real-time progesterone testing option gives me an
actual numeric result versus a range—and provides results right
away during the visit—enabling me to pinpoint ovulation and achieve
the best outcome for my breeder clients," said Dr. John F. Wilson, Owner of Wilson Veterinary
Hospitals in Washington Township,
MI.
In addition to needing a real-time test, veterinarians often
need to determine the ovulation window with a series of test
values, anywhere from two to as many as eight leading up to a
breeding opportunity. To support veterinarians' interest in such
serial testing, IDEXX has priced the Catalyst Progesterone Test
accordingly.
"Like the recent additions of the Catalyst® SDMA
Test, Catalyst® SDMA and Total T4 Kit, and
Catalyst® CRP Test, Catalyst Progesterone is yet another
proof point of our commitment to our customers: when they invest in
an IDEXX analyzer, the value appreciates over time with automatic
software advances and menu expansion," said Jonathan Ayers, Chairman and Chief Executive
Officer of IDEXX Laboratories. "We're thrilled to bring this highly
anticipated point-of-care diagnostic to veterinarians, advancing
the hospital's value to this client base."
There are 35,000 Catalyst chemistry analyzers in use globally,
and 98% are connected to IDEXX SmartService™
Solutions. All connected Catalyst customers will have the
capability to run the Catalyst Progesterone Test upon availability
via a behind-the-scenes software update via IDEXX SmartService
Solutions.
About IDEXX Laboratories, Inc.
IDEXX Laboratories, Inc. is a member of the S&P
500® Index and is a leader in pet healthcare innovation,
serving practicing veterinarians around the world with a broad
range of diagnostic and information technology-based products and
services. IDEXX products enhance the ability of veterinarians to
provide advanced medical care, improve staff efficiency, and build
more economically successful practices. IDEXX is also a worldwide
leader in providing diagnostic tests and information for livestock
and poultry and tests for the quality and safety of water and milk.
Headquartered in Maine, IDEXX
employs more than 8,000 people and offers products to customers in
over 175 countries. For more information about IDEXX, visit:
www.idexx.com.
Note Regarding Forward-Looking Statements
This news release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by the use of
words such as "expects," "may," "anticipates," "intends," "would,"
"will," "plans," "believes," "estimates," "should," and similar
words and expressions. These forward-looking statements are based
on management's current expectations and beliefs, as well as a
number of assumptions concerning future events. These
forward-looking statements involve known and unknown risks and
uncertainties that may cause the Company's actual results,
performance, or achievements to be materially different from those
expressed or implied by these forward-looking statements. IDEXX
assumes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events,
or otherwise. Readers are advised to review IDEXX's filings with
the United States Securities and Exchange Commission (which are
available from the SEC's EDGAR database
at www.sec.gov and via IDEXX's website
at www.idexx.com).
1 Data on file at IDEXX Laboratories, Inc.
Westbrook, Maine USA.
CONTACTS:
Media Relations
Robin Woodcock
207-632-8027
robin-woodcock@idexx.com
Investor Relations
Kerry Bennett
207-556-8155
kerry-bennett@idexx.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/idexx-introduces-exclusive-point-of-care-progesterone-test-to-its-catalyst-platform-300781045.html
SOURCE IDEXX Laboratories, Inc.